New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
07:41 EDTRDUSRadius Health reports Q2 EPS ($2.22), may not compare to consensus (89c)
The net loss per share calculation for the three months ended June 30 includes the weighted average impact of Radius' convertible preferred stock converting into common stock upon the completion of its initial public offering in June. The decrease in net loss for the 2014 period was primarily due to a decrease in research and development expenses.
News For RDUS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
16:09 EDTRDUSRadius Health price target raised to $52 from $26 at Cantor
Cantor doubled its price target on Radius Health to $52 from $26 after the company reported Phase III trial data the firm views as having significantly de-risked its development of abaloparatide-SC for the treatment of severe post-menopausal osteoporosis. Cantor maintains its Buy rating on Radius shares.
06:20 EDTRDUSRadius Health to host conference call
Subscribe for More Information
05:27 EDTRDUSRadius Health reports 'significant' progress towards abaloparatide development
Subscribe for More Information
05:23 EDTRDUSRadius Health ACTIVE Phase 3 clinical trial meets primary endpoint
Radius Health announced positive top-line 18-month fracture results from the company's Phase 3 clinical trial, known as ACTIVE, evaluating the investigational drug abaloparatide-SC for potential use in the reduction of fractures in postmenopausal osteoporosis. On the primary endpoint, the investigational drug abaloparatide-SC achieved a statistically significant 83% reduction of incident vertebral fractures as compared to the placebo-treated group. The ACTIVE trial included an open-label teriparatide injection treatment group that showed a statistically significant 78% reduction of incident vertebral fractures as compared to the placebo-treated group. On the secondary endpoints as compared to placebo, abaloparatide-SC achieved a statistically significant fracture-rate reduction of 43% in the adjudicated non-vertebral fracture subset of patients; a statistically significant reduction of 41% in the adjudicated clinical fracture group, which includes both vertebral and non-vertebral fractures; and a statistically significant difference in the time to first incident non-vertebral fracture in both the adjudicated non-vertebral fracture and the clinical fracture subset of patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use